Cervical Cancer
Conditions
Brief summary
The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with cervical cancer.
Detailed description
The primary objective is to evaluate whether RFA followed by CIK transfusion can prolong survival of patients with cervical cancer.
Interventions
PROCEDURERadiofrequency ablation
Radiofrequency ablation is performed percutaneously under CT/US guidance
BIOLOGICALCytokine-induced killer cells
The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
Sponsors
The First People's Hospital of Changzhou
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
30 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* They were systematic reviews based on randomized controlled trials (rcts). They were phase II rcts comparing chemotherapy with other systemic therapy agents or with no further treatment for recurrent, metastatic, or persistent cervical cancer. they reported at least one of these outcomes: complete or partial response rate, overall or progression-free survival rate, adverse effects, or healthrelated quality of life (rcts reporting on heterogeneous populations-for example, women at a range of disease stages-were included if results were given separately for patients with recurrent, metastatic, or persistent cervical cancer).
Exclusion criteria
* studies evaluating the role of radiotherapy administered with chemotherapy, or second- or subsequent-line therapy options.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Recurrence-free survival | 1 year | Recurrence-free survival (RFS) was defined as the time from the date of RFA to the date of recurrence or the date of the last follow-up. |
Outcome results
None listed